Circio Holding ASA
TA50
Company Profile
Business description
Circio Holding ASA is a biotechnology company developing circular RNA expression technology for gene and cell therapy applications. It has developed a circular RNA (circRNA) vector expression platform known as circVec, which is based on modular genetic constructs designed for circRNA production within target cells. The platform is being developed for applications including genetic medicine, cell therapy, and chronic disease treatment. The company's activities also include the development of RNA, DNA, and viral therapeutic technologies related to gene expression and protein production.
Contact
c/o Mesh Community AS
Tordenskiolds Gate 2
Oslo0160
NORT: +47 92951788
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,217.20 | 33.40 | -0.36% |
| CAC 40 | 8,286.40 | 5.77 | 0.07% |
| DAX 40 | 26,003.32 | 163.99 | 0.63% |
| Dow JONES (US) | 53,686.11 | 624.16 | 1.18% |
| FTSE 100 | 10,831.52 | 75.07 | 0.70% |
| HKSE | 25,213.31 | 97.90 | -0.39% |
| NASDAQ | 26,584.06 | 366.23 | 1.40% |
| Nikkei 225 | 64,741.75 | 527.27 | 0.82% |
| NZX 50 Index | 13,929.03 | 82.85 | 0.60% |
| S&P 500 | 7,747.71 | 81.11 | 1.06% |
| S&P/ASX 200 | 9,032.80 | 37.40 | -0.41% |
| SSE Composite Index | 3,942.09 | 0.70 | 0.02% |